Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Mid Cap Fund median (33 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 17 Mar 2025 – 20 Aug 2026, limited by Helios Mid Cap Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Helios Mid Cap Fund | Nifty Midcap 150 |
|---|---|---|
| 17 Mar 2025 | ₹100.00 | ₹100.00 |
| 29 Apr 2025 | ₹105.86 | ₹110.93 |
| 12 Jun 2025 | ₹114.71 | ₹119.25 |
| 25 Jul 2025 | ₹118.79 | ₹119.21 |
| 07 Sep 2025 | ₹122.07 | ₹117.38 |
| 20 Oct 2025 | ₹127.14 | ₹121.55 |
| 03 Dec 2025 | ₹127.63 | ₹122.69 |
| 15 Jan 2026 | ₹122.37 | ₹121.78 |
| 27 Feb 2026 | ₹120.08 | ₹121.12 |
| 12 Apr 2026 | ₹118.69 | ₹118.09 |
| 25 May 2026 | ₹128.53 | ₹125.82 |
| 08 Jul 2026 | ₹133.40 | ₹124.95 |
| 20 Aug 2026 | ₹139.26 | ₹129.67 |
| Metric | Helios · Regular · IDCW NAV ₹14.01 Very High risk ★★★★★ 1Y | Category median Mid Cap Fund · 33 funds |
|---|---|---|
| +13.35% | +4.36% | |
| — | +14.16% | |
| — | +13.38% | |
| — | +7.79% | |
| +26.14% | +9.71% | |
| +21.49% | — | |
| — | +11.96% | |
| — | +10.86% | |
| — | +9.43% | |
| Risk | ||
| 16.25% | 17.59% | |
| 0.42 | 0.44 | |
| 0.61 | 0.61 | |
| -17.15% | -47.34% | |
| Nifty Midcap 150 | — | |
| — | -3.13% | |
| — | 0.97 | |
| — | 91.4% | |
| — | 102.1% | |
| 2.47% | 2.04% | |
| ₹1,458Cr | ₹9,315Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹1.00K | — | |
| ₹5.00K | — | |
| 40% | 41% | |
| Alok Bahl · 0.9y | — | |
| 17 Mar 2025 | — | |
| 68 | — | |
| 25.2% | — | |
| 1.3% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.